KING SALES FORCE Sample Clauses

KING SALES FORCE. (a) Except as agreed to by the parties and subject to the terms and conditions of this Agreement, KING shall be solely responsible for the costs and expenses of establishing, maintaining and training KING's (and its Affiliates') sales force of sufficient size to perform its obligations hereunder, and conducting KING's other activities under this Agreement; provided, however, that (i) such training shall be conducted in accordance with Section 5.1 and (ii) the content and strategic direction of any training provided by KING that relates specifically to the Copromote Products shall be coordinated with the PMC. Notwithstanding the foregoing, KING shall pay incentive compensation to its sales representatives having primary responsibility for Detailing the Copromote Products with respect to sales of the Copromote Products in the Territory in accordance with KING's Sales Incentive Compensation Plan for KING's own prescription drug products, it being understood that KING shall determine the target payout for the Copromote Products in a manner consistent with the way in which it determines the target payouts for prescription drug products of comparable commercial potential. (b) To the extent practicable, all written, electronic and visual
Sample 1Sample 2
AutoNDA by SimpleDocs
KING SALES FORCE. (a) Except as otherwise agreed to by the parties and subject to the terms and conditions of this Agreement, KING shall be solely responsible for the costs and expenses of establishing, maintaining and training KING's (and its Affiliates') sales force of sufficient size to perform its obligations hereunder, and conducting KING's other activities under this Agreement; provided, however, that such training shall be conducted in accordance with Section 5.1. Notwithstanding the foregoing, KING shall pay incentive compensation to its sales representatives having primary responsibility for Detailing the Product with respect to sales of the Product in the Territory in accordance with KING's Sales Incentive Compensation Plan ("SICP") for KING's own products, it being understood that KING shall determine the target payout for the Product in a manner consistent with the way in which it determines the target payouts for prescription drug products of comparable commercial potential. (b) To the extent practicable, all written, electronic and visual communications provided to any of KING's sales representatives regarding strategy, positioning or selling messages for the Product will, at the request of the AMC, be subject to review by the AMC and AHPC's Copy Clearance Committee in accordance with Section 5.2(a).
Sample 1
KING SALES FORCE. (a) Except as otherwise agreed to by the Parties and subject to the terms and conditions of this Agreement, King shall be solely responsible for the costs and expenses of establishing, maintaining and training King’s (and its Affiliates’) sales force of sufficient size to perform its obligations hereunder, and conducting King’s other activities under this Agreement; provided, however, that such training shall be conducted in accordance with Section 5.1. Notwithstanding the foregoing, during the Copromotion Period King, shall pay incentive compensation to its sales representatives having primary responsibility for Detailing the Product(s) with respect to sales of the Product(s) in the Territory in accordance with King’s Sales Incentive Compensation Plan (“SICP”) for King’s own products, it being understood that King shall determine the target payout for the Product(s) in a manner consistent with the way in which it determines the target payouts for prescription drug products of comparable commercial potential and relative (based on commercial value) to other prescription drug products promoted by the King sales force. (b) To the extent practicable, all written, electronic and visual communications provided to any of King’s sales representatives during the Copromotion Period regarding strategy, positioning or selling messages for the Product(s) will, at the request of the AMC, be subject to review by the AMC (for so long as the AMC is in existence). Additionally, to the extent practicable, all written, electronic and visual communications provided to any of King’s sales representatives prior to June 30, 2006, regarding strategy, positioning or selling messages for the Product(s) will be subject to review by Wyeth’s Copy Clearance Committee in accordance with Section 5.2(a). After June 30, 2006 all written, electronic and visual communications provided to any of King’s sales representatives regarding strategy, positioning or selling messages for the Product(s) will be subject to review by King’s Copy Clearance Committee in accordance with Section 5.2(a), provided, however, that to the extent any such communications are provided to any of Wyeth’s (and its Affiliates) sales representatives regarding strategy, positioning or selling messages for the Product(s) and/or contain the name of Wyeth or any of Wyeth’s Affiliates or contain any of Wyeth’s Trademarks, such communications also shall be subject to review and approval by Wyeth’s Copy Clearance Committee in a...
Sample 1

Related to KING SALES FORCE

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.

  • Net Sales The term “

  • Contract Sales Price The total consideration provided for in the sales contract for the sale of a Property.

  • Contract Year A twelve (12) month period during the term of the Agreement commencing on the Effective Date and each anniversary thereof.

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • CONTRACT SALES REPORTING Contractor shall report total contract sales quarterly to Enterprise Services, as set forth below.

  • Combination Product The term “

  • Gross Sales Notwithstanding anything in the Lease to the contrary the definition of Gross Sales shall be as follows:

  • Contract Quarterly Sales Reports The Contractor shall submit complete Quarterly Sales Reports to the Department’s Contract Manager within 30 calendar days after the close of each State fiscal quarter (the State’s fiscal quarters close on September 30, December 31, March 31, and June 30). Reports must be submitted in MS Excel using the DMS Quarterly Sales Report Format, which can be accessed at xxxxx://xxx.xxx.xxxxxxxxx.xxx/business_operations/ state_purchasing/vendor_resources/quarterly_sales_report_format. Initiation and submission of the most recent version of the Quarterly Sales Report posted on the DMS website is the responsibility of the Contractor without prompting or notification from the Department’s Contract Manager. If no orders are received during the quarter, the Contractor must email the DMS Contract Manager confirming there was no activity.

  • Reformulation of Products As of the Effective Date, and continuing thereafter, Products that Xxxxx directly manufactures, imports, distributes, sells, or offers for sale in California shall either: (a) be Reformulated Products pursuant to § 2.2, below; or (b) be labeled with a clear and reasonable exposure warning pursuant to §§ 2.3 and 2.4, below. For purposes of this Settlement Agreement, a “Reformulated Product” is a Product that is in compliance with the standard set forth in

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!